Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis by Ford, John A et al.
Drug treatment of macular oedema
secondary to central retinal vein
occlusion: a network meta-analysis
Ford, J. A., Shyangdan, D., Uthman, O. A., Lois, N., & Waugh, N. (2014). Drug treatment of macular oedema
secondary to central retinal vein
occlusion: a network meta-analysis. BMJ Open, 4(7), [e005292]. DOI: 10.1136/bmjopen-2014-005292
Published in:
BMJ Open
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2014 The Authors
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms,
provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
Drug treatment of macular oedema
secondary to central retinal vein
occlusion: a network meta-analysis
John A Ford,1 Deepson Shyangdan,2 Olalekan A Uthman,2 Noemi Lois,3
Norman Waugh2
To cite: Ford JA,
Shyangdan D, Uthman OA,
et al. Drug treatment of
macular oedema secondary
to central retinal vein
occlusion: a network meta-
analysis. BMJ Open 2014;4:
e005292. doi:10.1136/
bmjopen-2014-005292
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2014-
005292).
Received 20 March 2014
Revised 27 June 2014
Accepted 30 June 2014
1Department of Population
Health and Primary Care,
University of East Anglia,
Norwich, UK
2Warwick Evidence,
University of Warwick,
Coventry, UK
3Centre for Vision and
Vascular Science, Queen’s
University, Belfast, UK
Correspondence to
Dr John Ford;
John.ford@uea.ac.uk
ABSTRACT
Objective: To indirectly compare aflibercept,
bevacizumab, dexamethasone, ranibizumab and
triamcinolone for treatment of macular oedema
secondary to central retinal vein occlusion using a
network meta-analysis (NMA).
Design: NMA.
Data sources: The following databases were searched
from January 2005 to March 2013: MEDLINE,
MEDLINE In-process, EMBASE; CDSR, DARE, HTA,
NHSEED, CENTRAL; Science Citation Index and
Conference Proceedings Citation Index-Science.
Eligibility criteria for selecting studies: Only
randomised controlled trials assessing patients with
macular oedema secondary to central retinal vein
occlusion were included. Studies had to report either
proportions of patients gaining ≥3 lines, losing ≥3
lines, or the mean change in best corrected visual
acuity. Two authors screened titles and abstracts,
extracted data and undertook risk of bias assessment.
Bayesian NMA was used to compare the different
interventions.
Results: Seven studies, assessing five drugs, were
judged to be sufficiently comparable for inclusion in
the NMA. For the proportions of patients gaining ≥3
lines, triamcinolone 4 mg, ranibizumab 0.5 mg,
bevacizumab 1.25 mg and aflibercept 2 mg had a
higher probability of being more effective than sham
and dexamethasone. A smaller proportion of patients
treated with triamcinolone 4 mg, ranibizumab 0.5 mg
or aflibercept 2 mg lost ≥3 lines of vision compared to
those treated with sham. Patients treated with
triamcinolone 4 mg, ranibizumab 0.5 mg, bevacizumab
1.25 mg and aflibercept 2 mg had a higher probability
of improvement in the mean best corrected visual
acuity compared to those treated with sham
injections.
Conclusions: We found no evidence of differences
between ranibizumab, aflibercept, bevacizumab and
triamcinolone for improving vision. The antivascular
endothelial growth factors (VEGFs) are likely to be
favoured because they are not associated with steroid-
induced cataract formation. Aflibercept may be
preferred by clinicians because it might require fewer
injections.
Systematic review registration: Not registered.
INTRODUCTION
Central retinal vein occlusion (CRVO) dra-
matically reduces an individual’s functioning
and quality of life.1 It is estimated that the
15-year cumulative incidence of CRVO is
0.5%.2 Visual loss is caused by thrombosis of
the central retinal vein which leads to a rise
in venous pressure and an increase in vascu-
lar endothelial growth factor (VEGF), conse-
quently causing an increase in vascular
permeability. Macular oedema subsequently
ensues with varying degrees of ischaemia and
neovascularisation. Although CRVO is gener-
ally classiﬁed as ischaemic or non-ischaemic,
ischaemia should be regarded as a spec-
trum.3 Cases with ischaemia carry a consider-
ably worse prognosis as, in around one-third
of them, neovascular glaucoma, the most
devastating complication of CRVO, may
develop.4
CRVO is more common in older people
with risk factors such as diabetes, hyperten-
sion or hyperlipidaemia, but can occur in
young people with inﬂammatory disorders.
Hayreh et al, in a 27-year cohort study, found
that only 13% of people with CRVO were
under 45 years of age.3 In 95% of cases,
CRVO affects only one eye.3 However, visual
loss in this already comorbid patient group
signiﬁcantly compounds their already
impaired functioning and quality of life.
Patients can lose conﬁdence, struggle with
Strengths and limitations of this study
▪ Important topic area, with significant policy
implications.
▪ Robust method used to identify studies.
▪ Network meta-analyses are based on a number
of assumptions.
▪ Network meta-analysis is the best method to
compare interventions in the absence of head-to-
head trials.
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daily activities and become increasingly dependent on
friends and family.1
For many years, laser photocoagulation was the only
effective therapeutic strategy that could be used in the
management of patients with CRVO. It was only useful
for reducing the risk of neovascular glaucoma, but not
effective for the treatment of macular oedema in
CRVO.5 Over the past decade, a number of drugs to
treat macular oedema have been introduced, including
the steroids, triamcinolone and dexamethasone, and the
anti-VEGFs, ranibizumab, bevacizumab, pegaptanib and
aﬂibercept. Dexamethasone, ranibizumab and aﬂiber-
cept have been assessed in large commercially funded
trials.6–13 Bevacizumab was originally developed as an
anticancer drug and has been found to be effective in
treating macular oedema secondary to age-related
macular degeneration,14 diabetic macular oedema,15
branch retinal vein occlusion16 and CRVO.17 Like triam-
cinolone, bevacizumab is used off license in the eye.
Ranibizumab is derived from the same parent molecule
of the bevacizumab monoclonal antibody and was devel-
oped and commercially marketed speciﬁcally for use in
the eye.
In the UK, the National Institute of Health and Care
Excellence (NICE) has recommended the use of dexa-
methasone, ranibizumab and aﬂibercept for the treat-
ment of macular oedema secondary to CRVO in
separate appraisals.18–20 Therefore clinicians have three
NICE-recommended treatments for CRVO without
head-to-head trials or clear guidance in which one may
be best for their patients. On this basis, the aim of this
study was to indirectly compare, in a network
meta-analysis (NMA), the clinical effectiveness of aﬂiber-
cept, ranibizumab, bevacizumab, dexamethasone and
triamcinolone for the treatment of macular oedema sec-
ondary to CRVO.
METHODS
Information sources and search strategy
To identify suitable studies, initially for a systematic
review of treatment of macular oedema after CRVO
(submitted for publication), the following databases
were searched from January 2005 to March 2013:
MEDLINE, MEDLINE In-process, EMBASE (all via
OVID); CDSR, DARE, HTA, NHSEED, CENTRAL (all
via The Cochrane Library); Science Citation Index and
Conference Proceedings Citation Index-Science (via
Web of Knowledge). The MEDLINE search strategy is
shown in the online supplementary appendix 1. This
search strategy was modiﬁed for other databases. In add-
ition to the bibliographic database searching, supple-
mentary searches were undertaken to look for recent
and unpublished studies in the WHO International
Clinical Trials Registry Platform and ophthalmology con-
ference websites (American Academy of Ophthalmology,
Association for Research in Vision and Ophthalmology
from 2010 to 2012).
Study selection
Only randomised controlled trials which included
patients with macular oedema secondary to CRVO were
included. It was acceptable for a study to include branch
retinal vein occlusion and CRVO provided that the
CRVO group was reported separately. The following
drugs were included: dexamethasone, triamcinolone,
ranibizumab, bevacizumab and aﬂibercept. Pegaptanib
was not included because it is not used routinely in clin-
ical practice. Only doses that are used in clinical practice
were included. Studies had to report at least one of the
following outcomes: proportions of patients gaining ≥3
lines from baseline to 6 months, proportions of patients
losing ≥3 lines from baseline to 6 months and the mean
change in best corrected visual acuity (BCVA) from base-
line to 6 months.
Risk of bias assessment
The Cochrane Collaboration’s tool was used for assessing
risk of bias.21 The trials were graded (unclear, high or
low risk of bias) based on: (1) sequence generation, (2)
allocation concealment, (3) blinding of outcome asses-
sor, (4) incomplete outcome data and (5) selective
outcome reporting.
Study selection and data abstraction
Two authors independently assessed the eligibility and
methodological quality of the studies identiﬁed during
the literature search. Two authors extracted and com-
pared the data. For each study identiﬁed that met the
selection criteria, details on study design, study popula-
tion characteristics, intervention, outcome measures and
study quality were extracted. Discrepancies were resolved
by consensus through discussion. Studies were assessed
for comparability based on the populations included,
trial arms, outcome measures and duration of follow-up.
Common comparators were identiﬁed from the trials
and a network diagram was created.
Summary measures
The primary measures of treatment effects were relative
risk (RR) for the proportions of patients gaining ≥3
lines of vision, proportions of patients losing ≥3 lines of
vision and the weighted mean difference (WMD) for
mean change BCVA. We used the following methods to
calculate SDs when incompletely reported: (1) contact
with the corresponding author or (2) estimation of the
SD on the basis of the sample size, median and range as
suggested by Hozo et al22 or on the basis of the sample
size and p value.
In one trial (SCORE),23–36 6-month data were not
available because patients were followed up every
4 months. For the dichotomous outcomes, that is, pro-
portions of patients gaining and losing ≥3 lines, we aver-
aged 4 and 8-month data to get the 6 months follow up
data. For the third outcome, that is, mean change
BCVA, again data from two time-points were used. The
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weighted mean and SDs for each treatment arm were
calculated using the mean and SDs of two time-points.
Data synthesis and model implementation
Bayesian NMA37 38 was used to compare the different
interventions. NMA is a generalisation of meta-analysis
methods because it allows comparisons of agents not
addressed within individual primary trials. Bayesian stat-
istical inference provides probability distributions for
treatment effect parameters (RR and WMD), with 95%
credible intervals (95% CrI), rather than 95% CIs
(95% CI). A 95% CrI can be interpreted as there being
a 95% probability that the parameter takes a value in
the speciﬁed range.37 38
All analyses were conducted using a Bayesian Markov
Chain Monte Carlo (MCMC) method and ﬁtted in the
freely available Bayesian software, WinBUGS V.1.4.3.39
Two Markov chains were run simultaneously using differ-
ent initial values. Convergence to a stable solution was
checked by viewing plots of the sampled simulations and
using the Brooks-Gelman-Rubin diagnostic tool.40
Convergence was found to be adequate after running
20 000 samples for both chains. These samples were then
discarded and a further 70 000 sampled simulation was
then run, on which the results were based. We also calcu-
lated the probability of treatment being the most effective
(ﬁrst best), the second best, the third best and so on, and
presented the results graphically with rankograms.41
Like standard meta-analysis comparison, an NMA can
be either a ﬁxed-effect or a random-effect model. We
used the Bayesian Deviation Information Criterion
(DIC) to compare ﬁxed-effect and random-effect
models. The most appropriate NMA model can be iden-
tiﬁed as the one with the lowest DIC. The DIC measures
the ﬁt of the model while penalising it for the number
of effective parameters. The ﬁxed-effect model was
chosen because of the small number of trials available
for each comparison, and difﬁculty in estimating
between studies variance, if random-effect model, was
implemented, and the difference in DIC was less than 5.
RESULTS
Study selection and characteristics
The literature search identiﬁed 945 articles, as shown in
ﬁgure 1. Seven studies were judged to be sufﬁciently
comparable to be included in the NMA. Tables 1 and 2
Figure 1 Study selection flow diagram.
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Table 1 Baseline characteristics and results of all included studies
Study Participants Intervention/outcomes
DEXAMETHASONE
GENEVA 20106–8
International
Setting: multicentre (167 centres in
24 countries, so a mean of 2.6
patients per centre)
Design: 2 identical double-blind,
sham-controlled RCTs, phase 3
Follow-up: primary endpoint for the
masked trial: 6 months; primary
endpoint for the open-label extension:
12 months
N: CRVO—437 eyes of 437 patients
randomised; 94% follow-up at 6 months
Participants: adults with visual acuity
reduced because of macular oedema
due to CRVO or BRVO
1. Dexamethasone 0.7 mg (n=136) Single
dose
2. Dexamethasone 0.35 mg (n=154)
Single dose
3. Sham (n=147) Single dose—a
needleless applicator was placed
against the conjunctiva to simulate the
placement of study medication.
Primary end point: gain of ≥15 ETDRS
letters; for the open-label extension: safety
TRIAMCINOLONE
SCORE 200923–36
USA
Setting: multicentre
Design: RCT
Follow-up: primary end point
12 months, FU planned up to
36 months
N: 271 eyes of 271 patients
randomised; 83% (observation) and
90% (triamcinolone) completed
12 months
Participants: centre-involved macular
oedema secondary to CRVO
1. Triamcinolone 1 mg (n=92) Every
4 months depending on retreatment
regimen (average 2.2 injections at
12 months)
2. Triamcinolone 4 mg (n=91) Every
4 months depending on retreatment
regimen (average 2.0 injections at
12 months) (The form of triamcinolone
used was Trivaris, no longer available.
It was made by the manufacturer of
Ozurdex (Allergan))
3. Observation (n=88)
Primary end point: gain of ≥15 ETDRS
letters
AFLIBERCEPT
COPERNICUS 201212 13
International
Setting: multicentre, 70 sites in North
and South America, India and Israel.
Mean 2.7 patients per centre
Design: double-blind, sham-controlled
RCT, phase 3
Follow-up: primary end point
24 weeks, FU 2 years
N: 189 eyes of 189 patients
randomised; 95.7% (aflibercept) and
81.1% (sham) completed 24 weeks;
93% (aflibercept) and 77% (sham)
completed 52 weeks
Participants: adult patients with
centre-involved CRVO for a maximum
of 9 months
1. Aflibercept 2 mg (n=114) Every 4 weeks
for 6 months (average number not
available)
2. Sham (n=73) Every 4 weeks for
6 months (average number not
available) (empty syringe without needle
pressed to conjunctival surface)
Primary end point: gain of ≥15 ETDRS
letters
GALILEO 201211
International
Setting: multicentre, 10 countries in
Europe and Asia; 63 centres in total
Design: double-blind, sham-controlled
RCT, phase 3
Follow-up: primary end point
24 weeks, FU up to 12 months,
planned up to 76 weeks
N: 177 eyes of 177 patients
randomised; 90.6% (aflibercept) and
78.9% (sham) completed 24 weeks
Participants: treatment-naïve patients
with centre-involved CRVO for a
maximum of 9 months
1. Aflibercept 2 mg (n=103) Every 4 weeks
for 6 months (average number not
available)
2. Sham (n=71) Every 4 weeks for
6 months (average number not
available) (empty syringe without needle
pressed to conjunctival surface)
Primary end point: gain of ≥15 ETDRS
letters
RANIBIZUMAB
CRUISE 20109 10
USA
Setting: multicentre
Design: double-blind, sham-controlled
RCT, phase 3
Follow-up: primary end point
6 months, FU up to 12 months
N: 392 eyes of 392 patients
randomised; 97.7% (ranibizumab
0.3 mg), 91.5% (ranibizumab 0.5 mg)
and 88.5% (sham) completed 6 months
Participants: patients with foveal
centre-involved macular oedema
secondary to CRVO diagnosed within
12 months
1. Ranibizumab 0.3 mg (n=132) Every
4 weeks for 6 months (average number
not available)
2. Ranibizumab 0.5 mg (n=130) Every
4 weeks for 6 months (average number
not available)
3. Sham (n=130) Every 4 weeks for
6 months (average number not
available) (empty syringe without needle
pressed to the injection site)
Primary end point: mean change from
baseline BCVA
Continued
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present the characteristics and results of the included
trials. Two studies11–13 compared aﬂibercept 2 mg
against sham; two identical studies6–8 compared dexa-
methasone 0.7 mg (Ozurdex) against sham; one
study9 10 compared ranibizumab 0.5 mg against sham;
one study42–44 compared bevacizumab 1.25 mg against
sham and, ﬁnally, one study23–36 compared triamcino-
lone 4 mg against observation. Sham or observation was
used as the common comparator. The number of
included participants varied from 6042–44 to 437.6–8 Most
studies required patients to be treatment naïve and have
macular oedema with retinal thickness measuring at least
250 or 300 μm on optical coherence tomography. Sham
injection was undertaken by placing a needleless syringe
on the eye. All studies, except for Epstein et al,42–44 were
multi-centre, international studies. Most studies had an
extension phase after the primary outcome, but this was
not included in the NMA.
The sufﬁciently comparable studies were combined
into a network analysis based on a common comparator.
The network for the proportions of patients gaining ≥3
lines is shown in ﬁgure 2. This network is the same for
the other two outcomes, but without dexamethasone,
because the trial did not report these outcomes.
Risk of bias of included trials
Risk of bias is shown in table 3. Included studies were
generally of high quality, with all studies being judged to
be of low or unclear bias for all criteria. The non-
commercially funded bevacizumab trial had fewer
patients and, inevitably, results had wider CIs.42–44 In no
study does it appear that patients were asked at the end
of the trial which arm they thought they had been
assigned. It is unclear how many could distinguish injec-
tions (intervention arm) from punctureless pressure
(sham arm).
Effects of interventions on proportions of patients
gaining ≥3 lines
Figure 3 displays a forest plot of the risk ratio and 95%
CrI in proportions of patients gaining ≥3 lines for all
the possible pairwise comparisons. In terms of propor-
tions of patients gaining ≥3 lines, triamcinolone 4 mg,
ranibizumab 0.5 mg, bevacizumab 1.25 mg and aﬂiber-
cept 2 mg had a higher probability of being more effect-
ive than a sham and dexamethasone (ﬁgure 4). There
was no difference in the proportions of patients gaining
≥3 lines between triamcinolone 4 mg, ranibizumab
0.5 mg, bevacizumab 1.25 mg and aﬂibercept 2mg.
Effects of interventions on proportions of patients
losing ≥3 lines
Figure 5 displays forest plot of the risk ratio and 95%
CrI of proportions of patients losing ≥3 lines for all the
possible pairwise comparisons. A smaller proportion of
patients treated with triamcinolone 4 mg, ranibizumab
0.5 mg or aﬂibercept 2 mg lost ≥3 lines of vision than
those treated with sham. There was no difference in the
proportions of patients losing ≥3 lines between triamci-
nolone 4 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg
and aﬂibercept 2 mg. Figure 6 shows ranking for efﬁcacy
in terms of proportions of patients losing ≥3 lines.
Effects of interventions on mean change in BCVA
Figure 7 displays a forest plot of the mean changes and
95% CrIs of improvement in BCVA for all the possible
pairwise comparisons. Patients treated with triamcino-
lone 4 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg or
aﬂibercept 2 mg had a higher probability of improve-
ment in BCVA compared to those treated with sham
injections. Patients treated with aﬂibercept 2 mg had a
higher probability of improvement in BCVA compared
with those treated with triamcinolone 4 mg (ﬁgure 8).
There was no difference in the mean change in BCVA
from baseline between patients treated with ranibizumab
0.5 mg, bevacizumab 1.25 mg and aﬂibercept 2 mg.
DISCUSSION
Statement of principal findings
Our results show no evidence of a difference in effective-
ness between aﬂibercept, ranibizumab and triamcino-
lone. Bevacizumab was similar to these drugs in terms of
Table 1 Continued
Study Participants Intervention/outcomes
BEVACIZUMAB
EPSTEIN 201242–44
Sweden
Setting: Single centre; St. Eriks Eye
Hospital Stockholm
Design: sham-injection controlled,
double maskedRCT
Follow-up: primary endpoint
6 months; open label extension up to
12 months
N: 60 eyes of 60 patients randomised;
93% completed open label extension
Participants: patients with CRVO of
≤6 months
1. Bevacizumab 1.25 mg (n=30) Every
6 weeks for 6 months (average number
not available)
2. Sham (n=30) Every 6 weeks for
6 months (averege number not
available) (syringe without needle
pressed to the globe)
Primary end point: gain of ≥15 ETDRS
letters
BCVA, best corrected visual acuity; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; ETDRS, Early Treatment
Diabetic Retinopathy Study; FU, follow-up; N, number; RCT, randomised controlled trial.
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Table 2 Baseline characteristics and results of included trials
Copernicus12 13 Galileo11 Cruise9 10 Geneva6–8 Epstein et al42–44 Score23–36
Baseline similarities
Number (%) of patients
Aflib 2 mg: 114 Aflib 2 mg: 103 Rani 0.5 mg: 130 Dexa 0.7 mg:
136
Beva 1.25 mg: 30 Triam 4 mg: 91
Sham: 73 Sham: 68 Sham: 130 Sham: 147 Sham: 30 Obser: 88
Age (years)
Aflib 2 mg: 65.5 SD 13.6 Aflib 2 mg: 59.9 SD
12.4
Rani 0.5 mg: 67.6
SD 12.4
Dexa 0.7 mg:
NR
Beva 1.25 mg: 70.6
SD 12.6
Triam 4 mg: 67.5 SD 12.0
Sham: 67.5 SD 14.3 Sham: 63.8 SD 13.3 Sham: 65.4 SD
13.1
Sham: NR Sham: 70.4 SD
10.4
Obser: 69.2 SD 12.8
BCVA at baseline (SD)
Aflib 2 mg: 50.7 SD 13.90 Aflib 2 mg: 53.6 SD
15.8
Rani 0.5 mg: 48.1
SD 14.6
Dexa 0.7 mg:
NR
Beva 1.25 mg: 44.4
SD 15.3
Triam 4 mg: 51.0 SD 14.4
Sham: 48.9 SD 14.42 Sham: 50.9 SD 15.4 Sham: 49.2 SD
14.7
Sham: NR Sham: 43.6 SD
16.0
Obser: 52.1 SD 13.1
Duration of MO from diagnosis to screening
Aflib 2 mg: 2.73 SD 3.09
(in months)
Aflib 2 mg: 50.9 SD
15.4) (in days)
Rani 0.5 mg: – Dexa 0.7 mg:
NR
Beva 1.25 mg: NR Triam 4 mg: 4.2 SD 3.6 (in months)
Sham: 1.88 SD 2.19 (in
months)
Sham: 87.6 SD 79.1
(in days)
Sham: – Sham: NR Sham: NR Obser: 4.2 SD 3.1 (in months)
Results
Number (%) of patients gaining ≥15 letters improvement from baseline to 6 months
Aflib 2 mg: 64 (56.1) Aflib 2 mg: 62 (60.2) Rani 0.5 mg: 62
(47.7)
Dexa 0.7 mg: 25
(18)
Beva 1.25 mg: 18
(60%)
Triam 4 mg: 18 (19.5%) (average of 4 and
8 months)
Sham: 9 (12.3) Sham: 15 (22.1) Sham: 22 (16.9) Sham: 18 (12) Sham: 6 (20%) Obser: 3 (4%) (average of 4 and 8 months)
Number (%) of patients losing ≥15 letters of BCVA from baseline to 6 months
Aflib 2 mg: 2 (1.8) Aflib 2 mg: 8 (7.8) Rani 0.5 mg: 2
(1.5)
Dexa 0.7 mg:
NR
Beva 1.25 mg: 2
(6.7%)
Triam 4 mg: 19 (20.5%) (average of 4 and 8
months)
Sham: 20 (27.4) Sham: 15 (22.1) Sham: 20 (15.4) Sham: NR Sham: 7 (23.3%) Obser: 31 (35.5%) (average of 4 and 8 months)
Mean change (SD) from baseline in BCVA
Aflib 2 mg: 17.3 (12.8) Aflib 2 mg: 18.0 (12.2) Rani 0.5 mg: 14.9
(13.2)
Dexa 0.7 mg: 0.1
(NR)
Beva 1.25 mg: 14.1
SD 18.7
Triam 4 mg: −0.15 SD 20.67 (n=85) (weight
mean and SD of 4 and 8 months)
Sham: −4 (18) Sham: 3.3 (14.1) Sham: 0.8 (16.2) Sham: −1.8
(NR)
Sham: −2.0 SD
20.5
Obser: −9.66 SD 18.04 (n=75) (weighted mean
and SD of 4 and 8 months)
Aflib, aflibercept; BCVA, best corrected visual acuity; Dexa, dexamethasone; NR, not reported; Obser, observation; Rani, ranibizumab; Triam, triamcinolone.
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letters gained and the mean change in BCVA.
Dexamethasone was less effective compared with these
drugs.
Strengths and limitations
This is the ﬁrst study providing an indirect comparison
of drugs to treat macular oedema secondary to CRVO. A
robust search strategy, screening process and data extrac-
tion were used, and this analysis drew on a systematic
review. The studies included had, in general, a low risk
of bias. Safety was not considered in this study but is
described in detail elsewhere.45 Five different drugs were
suitable for NMA. Unpublished data were obtained from
one author.42–44 Bayesian methods were used for the
NMA. There was good model ﬁt and convergence within
the analysis.
However, pre-speciﬁed outcomes were not reported in
all studies and the sample size varied considerably. For
example, Epstein et al, 42–44 assessing bevacizumab, only
included 30 participants in each arm. This resulted in
wide CrIs from the NMA, which could have led to a type
1 error, especially with regard to the proportions of
patients losing ≥3 lines. The SCORE study compared
triamcinolone to observation.23–36 The NMA assumes
a11 similar effect of sham and observation and this may
result in a small degree of bias. Only 6 months of data
were included, and the long-term effects are not known.
Using a 6-month follow-up period may disadvantage
dexamethasone because peak effect in the GENEVA
trials was seen at 90 days, and by 6 months, beneﬁts had
been largely lost.6–8
As with most network meta-analyses, methodological
heterogeneity was present. There were some differences
among the trials. For example, CRUISE,9 10 assessing
ranibizumab, did not include as many patients with
ischaemic CRVO as the aﬂibercept trials.12 13 There
were also some small differences in the chronicity of
macular oedema and the mean BCVA at baseline.
Meaning of the study: possible explanations and
implications for clinicians and policymakers
No head-to-head trials comparing aﬂibercept, bevacizu-
mab, ranibizumab, triamcinolone and dexamethasone
have been published in CRVO. Part of the reason for
this is that the Food and Drug Administration requires
proof of the safety and effectiveness of a drug.46 The
easiest and quickest method for pharmaceutical com-
panies to produce this proof is through placebo con-
trolled trials. Trials comparing new medications to
current best treatment would be considerably more
useful to clinicians and patients.
Head-to-head trials comparing some of these drugs
are available in other conditions. For example, a com-
parison of ranibizumab and bevacizumab was under-
taken in age-related macular degeneration in the
Comparison of Age-related macular degeneration
Treatment Trials (CATT)47 and alternative treatments to
Inhibit VEGF in patients with Age-related choroidal
Neovascularisation (IVAN)48 trials. Both of these trials
found no difference in effectiveness between ranibizu-
mab and bevacizumab. Furthermore, an indirect com-
parison of ranibizumab and bevacizumab found no
evidence of a difference between these drugs.49 Thus, it
is highly probable that this may also apply in CRVO. The
difference seen in our results regarding bevacizumab
may be due to the low number of patients included in
Epstein et al.42–44 In the CATT trial, more patients were
hospitalised in the bevacizumab arm, but the authors
did not believe that this was explained by a direct effect
of bevacizumab.47 The 2-year results from the IVAN
showed little difference in cardiovascular events, with
the number being insigniﬁcantly lower with bevacizu-
mab.50 Ranibizumab and aﬂibercept were directly com-
pared in two similarly designed trials, VEGF Trap-eye:
investigation of Efﬁcacy and safety in Wet age-related
macular degeneration (VIEW 1 and 2).51 Similar efﬁcacy
and safety was found in both drugs.
From the included trials it is clear that intraocular ster-
oids are associated with complications, including increased
intraocular pressure and cataract formation.6–8 23–36 These
are substantial drawbacks for using steroids to treat
macular oedema in CRVO. However, many affected
patients may already be pseudophakic and, on these, the
use of intraocular steroids may be reasonable. Steroids
may have a place in the treatment pathway of patients who
have failed on anti-VEGF therapy, but this is yet to be
tested. The anti-VEFG drugs have a good safety proﬁle and
do not cause cataract formation.9–13 42–44 For this reason
they are more likely to be favoured by clinicians than
steroids.
Aﬂibercept, compared with ranibizumab and bevaci-
zumab, targets a wider range of cytokines and may have
a stronger binding afﬁnity.52 Initial results suggested
that aﬂibercept would require fewer injections than
ranibizumab.51 Heier and colleagues compared aﬂiber-
cept and ranibizumab in two similarly designed rando-
mised controlled trials in age-related macular
degeneration. They found that 2 mg aﬂibercept admi-
nistered every 8 weeks produced similar effects at
96 weeks to 0.5 mg ranibizumab administered every
4 weeks.51 This was reﬂected in the FDA Dermatologic
and Ophthalmic Drugs Advisory Committee recom-
mendation that aﬂibercept should be given every
Figure 2 Network of randomised controlled trials comparing
different treatments for proportions of gaining three or more
lines of vision.
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Table 3 Risk of bias
Study
(author and
year)
Adequate
sequence
generation
Allocation
concealment Masking
Incomplete
outcome data
addressed
Free of
selective
reporting
Free of other bias (eg,
similarity at baseline,
power assessment) Funder
Geneva
20106–8
Low Low Partial: patients and
assessors of efficacy
variables
Low: ITT analysis,
94% FU at 6 months
Low Power: 81% power to
detect difference in
primary outcome with
n=495 for each trial
Similarity at baseline: yes
Allergan Inc
Score
200923–36
Low Unclear Partial (physicians and
patients masked to dose
but not triamcinolone vs
observation)
Low: ITT analysis,
83–90% FU at
12 months
Low Power: 80% power to
detect difference in
primary outcome with
n=486 (but only 271
randomised)
Similarity at baseline: yes
National Eye Institute
grants, Allergan
Copernicus
201212 13
Low Unclear Low: double-blind Low: ITT analysis,
89.9% assessed at
primary end point
Low Power: 90% power to
detect difference in
primary outcome with
n=165
Similarity at baseline: yes
Bayer HealthCare,
Regeneron
Pharmaceuticals
Galileo
201211
Unclear Unclear Low: double-blind Low: ITT analysis,
86% assessed at
primary end point
Low Power: 90% power to
detect difference in
primary outcome with
n=150
Similarity at baseline: yes
Bayer HealthCare,
Regeneron
Pharmaceuticals
Cruise
20109 10
Low Unclear Low: patients and
evaluating examiners,
injecting physicians
masked to dose
Low: ITT analysis,
88.5–97.7%
completed 6 months
Low Power: not reported
Similarity at baseline: yes
Genentech Inc.
Epstein
201242–44
Unclear Low Low: patients, outcome
assessors
Low: ITT analysis;
missing data for 2
patients (primary
endpoint)
Low Power: 80% power to
detect difference in
primary outcome with
n=24 per group
Similarity at baseline: yes
Unclear; authors are
consultants for Allergan,
Novartis, Alcon, Bayer
FU, follow-; ITT, intention to treat.
8
Ford
JA,etal.BM
J
Open
2014;4:e005292.doi:10.1136/bm
jopen-2014-005292
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 D
ecem
ber 9, 2014 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
2 months following three initial monthly doses in
age-related macular oedema.53 This may be because
aﬂibercept also appears to last longer in the eye than
ranibizumab.54 Age-related macular degeneration is a
more aggressive condition than CRVO and so it is
unlikely that more frequent dosing would be needed.
Therefore, aﬂibercept may be preferred because it
would reduce pressure on outpatient clinics.
Figure 3 Proportions of patients gaining three lines or more from baseline to 6 months.
Figure 4 Rankogram for gaining ≥3 lines—distribution of the probabilities of every treatment being ranked at each of the
possible six positions.
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Furthermore, there is some evidence from patients
with age-related macular degeneration that aﬂibercept
may be effective in patients who have not responded to
ranibizumab.55 56 This may be due to the higher afﬁn-
ity and wider number of cytokines that are targeted.
There is no reason to suspect that these effects are any
different for the macular oedema caused by CRVO.
However, we have as yet no evidence as to whether
ranibizumab would be effective after aﬂibercept has
failed.
The National Institute of Health and Care Excellence
has recommended dexamethasone, ranibizumab and
aﬂibercept as options in the treatment of macular
oedema secondary to CRVO.18–20 Until these technolo-
gies are reviewed together and compared with each
other, clinicians are left with three recommended drugs.
It should be noted that during the appraisal of ranibizu-
mab the evidence review group found that in the cost-
effectiveness analysis dexamethasone was extendedly
dominated by ranibizumab (an intervention is judged
not be cost-effective because it has an ICER that is
greater than that of a more effective intervention). The
committee appraising ranibizumab did not re-consider
the previous appraisal decision on dexamethasone.
Our results show that dexamethasone was not as
effective as ranibizumab or aﬂibercept, at 6 months
follow-up and with the dosing regimens in the trials.
However, these results do not assess quality of life or cost
effectiveness. Bevacizumab is likely to prove more cost
effective than both aﬂibercept and ranibizumab because
Figure 5 Proportions of patients losing three lines or more from baseline to 6 months.
Figure 6 Rankogram for losing ≥3 lines—distribution of the probabilities of every treatment being ranked at each of the possible
six positions.
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it is substantially less expensive.57 However, the National
Institute for Health and Care Excellence has not issued
guidance on bevacizumab because it does not have a
license for use in the eye.
Unanswered questions and future research
Not all patients beneﬁt from the use of anti-VEGF drugs;
only about 60% gain 15 or more letters. It is not clear
why some patients beneﬁt more than others. Future
Figure 7 Mean best corrected visual acuity change from baseline to 6 months.
Figure 8 Rankogram for mean change in best corrected visual acuity—distribution of the probabilities of every treatment being
ranked at each of the possible six positions.
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research should focus on identifying subgroups of
patients who are likely to beneﬁt. Only a few of the trials
included ischaemic patients, and in those trials only a
few patients with ischaemia were included.11–13 More
research assessing the effectiveness of these drugs in
severely ischaemic patients is needed.
Head-to-head trials comparing ranibizumab, aﬂiber-
cept, bevacizumab and triamcinolone are needed. These
should include assessment of cost effectiveness. To assist
this, a better measure of quality of life is needed for
patients with eye conditions. The widely used EQ5D may
not be sensitive enough to measure changes that are
important to patients, such as the ability to drive.
In conclusion, we have found no evidence of differences
between ranibizumab, bevacizumab, aﬂibercept and triam-
cinolone for improving vision. The anti-VEGFs are likely to
be favoured because they are not associated with
steroid-induced cataract formation. Clinicians may prefer
Aﬂibercept because it might require fewer injections.
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